Fonylin MR 60mg sustained-release tablets
Ferron Par Pharmaceuticals
Ingredients in every sustained-release tablet
| Gliclazide | 60 mg |
Each package contains
Other details
| Flavour | None |
W.H.O. classification
| ATC Level 1 | A - Alimentary tract and metabolism |
| ATC Level 2 | A10 - Drugs Used in Diabetes |
| ATC Level 3 | A10B - Blood Glucose Lowering Drugs; excl. Insulins |
Warnings
Pregnancy
Lactation
Alcohol
Machinery
Available in
 |
Indonesia |
Dosage information
UP TO 18 YEARS
There is no data on the safety and efficacy of use in children.
18 TO 65 YEARS OLD
Oral use only. The daily dose of gliclazide may vary from half to two tablets per day, i.e. from 30 to 120 mg taken orally in a single intake at breakfast time. The maximum recommended daily dose is 120 mg per day.
The recommended starting dose is 30 mg daily (half a tablet of Fonylin MR 60 mg).
As with any hypoglycemic agent, the dose should be adjusted according to the individual patient’s metabolic response (blood glucose, HbA1c).
65 YEARS OLD AND ABOVE
In patients over 65 years of age, Fonylin MR 60 mg should be prescribed using the same dosing regimen recommended for patients under 65 years of age.
ADMINISTRATION
It is recommended to swallow the tablet(s) without crushing or chewing. If a dose is forgotten, the dose taken the next day must not be increased.
PATIENTS WITH RENAL INSUFFICIENCY
In patients with mild to moderate renal insufficiency the same dosing regimen can be used as in patients with normal renal function with careful patient monitoring.
PATIENTS AT RISK OF HYPOGLYCEMIA
It is recommended to start the treatment systematically with the minimum dose of 30 mg per day.
Indication
Non-insulin-dependent diabetes (type 2) in Adults when dietary measures, physical exercise, and weight loss alone are not sufficient to control blood glucose.